Matthew J. Price – författare

This issue of Interventional Cardiology Clinics, edited by Matthew J. Price, is devoted to Intravascular Imaging. Dr. Price assembled a group of expert contributors to review the following topics: IVUS for the assessment of coronary lesion severity and optimization of PCI; IVUS for the diagnosis and treatment of left main coronary artery disease; Fundamentals of OCT: image acquisition and interpretation; Technique and Best Practices for Intracoronary OCT; Assessment and quantitation of stent results by intracoronary OCT; PCI planning and optimization with intracoronary OCT; Advances in Automated Assessment of Intracoronary OCT and Their Clinical Application; Diagnosis and evaluation of stent thrombosis using OCT; Acute and long-term evaluation of bioresorbable scaffolds by OCT; Role of OCT in the diagnosis, evaluation, and management of spontaneous coronary artery dissection; and Neointimal Coverage after Drug-Eluting Stent Implantation: Insights from Optical Coherence Tomography.

This issue of Interventional Cardiology Clinics, edited by Drs. Dominick Angiolillo and Matthew Price, will focus on Antiplatelet and Anticoagulation Therapy in PCI. The topics covered in this volume will span across pretreatment with antiplatelet agents; optimal duration of antiplatelet therapy after PCI; Cangrelor and its role in percutaneous coronary intervention; Ticagrelor and its effects beyond the P2Y12 receptor; dyspnea and Reversibly-binding P2Y12 antagonists; PAR receptor inhibition post-PCI; switching P2Y12 receptor inhibiting therapies; antiplatelet and antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting; antithrombotic therapy to reduce ischemic events in ACS patients undergoing PCI; and the current role of platelet function testing in PCI and CABG, among other topics.

This issue of Interventional Cardiology Clinics, edited by the series Editor-in-Chief, Dr. Matthew Price, will cover Transcatheter Closure of Patent Foramen Ovale. Some of the topics discussed in this issue include, but are not limited to, PFO and the Interatrial Septum: Clinical-Anatomic Correlations; Current Dataset for PFO Closure in Cryptogenic; Stroke: Randomized Clinical Trials and Observational Studies; PFO closure: Devices and Technique; Identification and quantification of PFO-mediated shunts: echocardiography and transcranial Doppler; PFO closure for Hypoxemia; and Imaging Assessment of the interatrial Septum for ASD and PFO closure, among others.

This issue of Interventional Cardiology Clinics, edited by Jorge Gonzalez and Matthew Price, will span a number of essential topics surrounding Imaging in Intervention. Subjects discussed include: Multimodality Imaging for Transcatheter Mitral Valve Replacement; CT Assessment for Transcatheter Aortic Valve Replacement; Imaging Evaluation and Interpretation for Vascular Access for TAVR; Imaging Evaluation for the Detection of Leaflet Thrombosis after TAVR; CT Imaging Guidance for WATCHMAN LAA Closure; Myocardial viability testing to guide coronary revascularization; Intravascular Ultrasound For Guidance and Optimization of Percutaneous Coronary Intervention; CT-FFR to guide coronary angiography and intervention; Multimodality imaging of the tricuspid valve for assessment and guidance of transcatheter repair; and Three-dimensional printing for structural heart intervention planning, among others.

This issue of Interventional Cardiology Clinics will explore Updates in Percutaneous Coronary Intervention. Curated by the series Editor-in-Chief, Dr. Matthew J. Price, this issue will cover topics and advances in the field that are relevant for practicing clinicians. This issue is one of four selected each year by Dr. Price. The volume will include articles on: Current Concepts in Intraprocedural Pharmacology During PCI; Periprocedural Myocardial Infarction in Contemporary Practice; Newer Generation Metallic Stents: Design, Performance Characteristics, and Outcomes; Distal Transradial Access for Coronary Angiography and Intervention; Clinical Outcomes Data for iFR-guided PCI; Culprit-only or Complete Revascularization During STEMI in Patients with and Without Shock; Technical Approaches to Left Main Coronary Intervention: Contemporary Best Practices; Robotic Assisted Percutaneous Coronary Intervention; Orbital Atherectomy: A Comprehensive Review; and Percutaneous revascularization of spontaneous coronary artery dissection, among others.

This issue of Interventional Cardiology Clinics will review some of the hottest topics currently in Interventional Cariology. Curated by the series Editor-in-Chief, Dr. Matthew J. Price, this issue will cover topics and advances in the field that are relevant for practicing clinicians. This issue is one of four selected each year by Dr. Price. The volume will include articles on: IV antiplatelet therapy during PCI; Pharmacodynamics during transition between P2Y12 therapies; Balloon valve fracture for TAVR valve-in-valve; Transcatheter Closure of Patent Foramen Ovale - Randomized Trial Update; Adjunct Pharmacotherapy after TAVR: Current Status and Future Directions; Transcatheter approaches to the treatment of mitral valve leaflet perforation; �Transcatheter Aortic Valve Replacement with the Lotus Valve; Conduction system abnormalities after TAVR, among other topics.

This issue of Interventional Cardiology Clinics, guest edited by Editor-in-Chief Matthew J. Price, will focus on Key Trials of the Decade. Trials discussed in this issue will include: Physiology over Angiography to determine lesion severity: The FAME trials; Percutaneous Coronary Intervention or surgery for multivessel disease: The SYNTAX trial at 10 years; Percutaneous Coronary Intervention or surgery for unprotected left main disease: The EXCEL trial at 5 years; Complete or Incomplete Revascularization for ST-Elevation Myocardial Infarction: the PRAMI trial and beyond; Abbreviated Dual Antiplatelet Therapy after PCI in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE; Transcatheter treatment of functional mitral regurgitation in patients with heart failure: The COAPT trial; Manual thrombectomy in Primary Percutaneous Coronary Intervention: Lessons learned from TOTAL; Paradigm shifts in the treatment of aortic stenosis: The PARTNER Trials experience; COURAGE and ORBITA in context: PCI for chronic stable CAD; SIMPLICITY to RADIANCE: Interpreting the past and mapping the future of renal denervation; From WOEST to AUGUSTUS: Dual Therapy after PCI; The ISCHEMIA Trial: Background, Design, Outcomes and Clinical Interpretation.

Increasing data and recent technological advances have resulted in exciting changes in the field of interventional cardiology, from new research and equipment to new procedures, applications, and approaches. Textbook of Interventional Cardiology, 9th Edition, brings you fully up to date with the latest treatment protocols for managing patients at every level of complexity. Drs. Paul S. Teirstein, Matthew J. Price, and Eric J. Topol lead a team of contributing authors who provide expert coverage of this rapidly changing field for fellows and practicing interventional cardiologists, cardiac surgeons, vascular surgeons, interventional radiologists, referring physicians, and advanced practitioners.

Make optimal use of the latest coronary stenting techniques and adjunctive devices with well-rounded guidance from Coronary Stenting, a companion volume to Dr. Topol�s Textbook of Interventional Cardiology. This comprehensive, up-to-date interventional cardiology book keeps you abreast of the latest trial data on efficacy and safety as well as cutting-edge clinical applications in coronary stenting.

"This book guides you through everything in percutaneous intervention that you need to know." Reviewed by Perfusion, Apr 2015

Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are warfarin-eligible. This approval is projected to significantly expand the indications for LAA closures worldwide. Thus, the volume of procedures is anticipated to escalate. This book discusses the epidemiology of AF as a cause of stroke; the use of LAA closure in the reduction of thromboembolism with AF; early surgical approaches and novel surgical devices for LAA closure; and current percutaneous approaches and devices available for LAA closure. The emphasis of this book is on percutaneous technical approaches and contemporary trial results on the leading devices (PLAATO, WATCHMAN, Amplatzer Cardiac Plug, and LARIAT). It also reviews unapproved devices in development, in both clinical and pre-clinical phases.

Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are warfarin-eligible. This approval is projected to significantly expand the indications for LAA closures worldwide. Thus, the volume of procedures is anticipated to escalate. This book discusses the epidemiology of AF as a cause of stroke; the use of LAA closure in the reduction of thromboembolism with AF; early surgical approaches and novel surgical devices for LAA closure; and current percutaneous approaches and devices available for LAA closure. The emphasis of this book is on percutaneous technical approaches and contemporary trial results on the leading devices (PLAATO, WATCHMAN, Amplatzer Cardiac Plug, and LARIAT). It also reviews unapproved devices in development, in both clinical and pre-clinical phases.